Objective-The objective of this study is to investigate the role of T-cell ubiquitin ligand-2 (TULA-2) in the platelet Fc receptor for IgG IIA (FcγRIIA) pathway and in the pathogenesis of heparin-induced thrombocytopenia (HIT). Approach and Results-HIT is a life-threatening thrombotic disease in which IgG antibodies against the heparin-platelet factor 4 complex activate platelets via FcγRIIA. We reported previously differential expression of TULA-2 in human population was linked to FcγRIIA responsiveness. In this study, we investigated the role of TULA-2, a protein phosphatase, in the FcγRIIA pathway and HIT pathogenesis by crossing TULA-2 −/− mice with transgenic FcγRIIA +/+ mice. Ablation of TULA-2 resulted in hyperphosphorylation of spleen tyrosine kinase, linker for the activation of T cells, and phospholipase Cγ2 in platelets via FcγRIIA activation. Platelet integrin activation, granule secretion, phosphatidylserine exposure, and aggregation were also enhanced in TULA-2 −/− murine platelets. Compared with wild-type mice, TULA-2 −/− mice showed aggravated antibody-mediated thrombocytopenia, augmented thrombin generation, and shortened tail bleeding time. In contrast, there was no significant difference between TULA-2 −/− and TULA-2 +/+ platelets in platelet spreading and clot retraction. Of note, heterozygous TULA-2 +/− mice, whose platelets contained 50% as much protein as the TULA-2 +/+ platelets, showed significantly increased platelet reactivity and more severe thrombocytopenia in vivo compared with TULA-2 +/+ mice. Conclusions-Together, the data demonstrate that not only the absence of TULA-2 but also the relative level of TULA-2 expression modulates FcγRIIA-mediated platelet reactivity and HIT in vivo. TULA-2 expression could be a valuable marker for HIT and inhibiting TULA-2 may serve as a potential therapy to reverse the bleeding adverse effect of anticoagulants.
P latelets play an essential role in hemostasis, wound healing, thrombus formation, and many cardiovascular diseases. Among platelet-activating receptors, Fc receptor for IgG IIA (FcγRIIA; CD32a), an Fc receptor for the constant region of immunoglobulin G on platelets, is implicated in immune-mediated thrombocytopenia and thrombosis disorders, 1-3 internalization of immune complexes, 4 platelet spreading, 5 and inflammatory response and host defense against bacteria. 6, 7 The FCGR2A gene, which encodes FcγRIIA in humans, is absent in mice. 1 The FcγRIIA pathway has been demonstrated as a crucial mediator of the heparin-induced thrombocytopenia (HIT), which is a severe adverse effect of heparin treatment. 8 In HIT, intravascular platelet activation and aggregation are triggered via FcγRIIA by IgG antibodies binding to heparin-platelet factor 4 complexes. 9 On activation, the immunoreceptor tyrosine-based activation motifs (ITAMs) in FcγRIIA are phosphorylated and further provide docking sites for the spleen tyrosine kinase (Syk). Docked Syk is phosphorylated at various tyrosine residues, becomes an active protein kinase, and triggers downstream signal transduction. 10, 11 Phospholipase Cγ2 (PLCγ2) is phosphorylated after Syk activation and further produces the second messengers inositol 1,4,5-trisphosphate and 1,2-diacylglycerol. Calcium mobilization and protein kinase C activation follow. Subsequently, platelets secrete dense and α-granules, integrin α IIb β 3 is activated and ready to bind to fibrinogen and fibrin, and platelet activation is achieved. 12 Other important signaling molecules in the FcγRIIA-Syk pathway include the linker for the activation of T cells (LAT), SH2 domain-containing leukocyte protein of 76 kDa, and phosphatidylinositide 3-kinases. [13] [14] [15] [16] The central role of Syk activity in HIT was established by our studies that a Syk inhibitor prevented the disease in our transgenic mouse model. 17 As a result of immune complex-mediated December 2016
FcγRIIA activation, thrombus formation and excessive thrombin generation put patients at high risk for limb-and lifethreatening complications.
T-cell ubiquitin ligand-2 (TULA-2 or STS-1) is encoded by the UBASH3B gene and functions by dephosphorylating tyrosine residues on other proteins. TULA-2 is the only member of the TULA family of protein tyrosine phosphatases detected in human and mouse platelets. 18 Previously, we reported that TULA-2 was downregulated in human donors hyper-responsive to platelet FcγRIIA stimulation. 19 We hypothesized that TULA-2 negatively regulates the platelet FcγRIIA pathway and HIT pathogenesis via dephosphorylation of Syk. Because the mouse genome lacks a FCGR2A gene, we crossed the murine knockout of TULA-2 with humanized FcγRIIA transgenic mice to elucidate the effect of TULA-2 on the platelet FcγRIIA pathway. Here, we report that decreased TULA-2 level resulted in increased platelet reactivity, aggravated thrombocytopenia and thrombosis in vivo, and shortened tail bleeding time.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

TULA-2 Knockout Modulates the FcγRIIA Signaling Pathway in Murine Platelets
In this study, we crossed TULA-2 −/− C57BL/6 mice with transgenic FcγRIIA (IIA +/+ ) C57BL/6 mice to generate 3 different genotypes of mice: TULA-2 −/− , TULA-2 +/− , and TULA-2 +/+ (wild-type [WT]) mice, all are IIA +/+ . TULA-2 −/− , IIA +/+ mice did not show any significant embryonic defects or lethality. The age-adjusted weight, litter size, and the basal blood cell profiles are all comparable to the WT TULA-2 +/+ . Specifically, platelet count, white blood cell differential (including neutrophils, monocytes, and lymphocytes), and red blood cell count were not changed between TULA-2 knockout and TULA-2 WT mice (Figure I in the online-only Data Supplement). The mean platelet volume and mean red blood cell volume were also not significantly different.
For signaling studies, we used the mouse monoclonal anti-FcγRIIA antibodies (IV.3) crosslinked by goat antimouse Fab' 2 (GAM) to induce platelet activation via FcγRIIA. To understand the global changes in tyrosine phosphorylation, we first used an antiphosphotyrosine antibody to blot the whole-platelet lysate after IV.3+GAM treatment ( Figure II in the online-only Data Supplement). Next, we used protein-specific antibodies to investigate the changes of phosphorylation pattern in selected proteins. Figure 1A shows a time course of protein phosphorylation in activated platelets stimulated by IV.3+GAM. Compared with TULA-2 +/+ , the TULA-2 −/− platelets showed significantly higher Syk phosphorylation at tyrosine (Y) 519/520 at all time points. Y519/520 is the murine equivalent of human Y525/526 in Syk, which are correlated with Syk kinase activity. 20 Two other downstream effectors, PLCγ2 and LAT were also examined. Similar to Syk, phosphorylation of PLCγ2 at Y759 and LAT at Y191 were increased in the absence of TULA-2. Quantification of phosphorylated Syk and PLCγ2 showed a 3-to 4-fold increase in TULA-2 −/− platelets compared with TULA-2 +/+ controls from 60s to 480s ( Figure 1B and 1F).
TULA-2 Heterozygous Knockout Platelets Demonstrate Increased Phosphorylation of FcγRIIA Signaling Nodes
To further scrutinize the effects of the level of expression of TULA-2 on the FcγRIIA pathway, we compared the molecular reactivity in the FcγRIIA pathway between the TULA-2 heterozygous knockout (TULA-2 +/− ) mice and the WT mice. Murine TULA-2 +/− platelets express 50% as much protein as their TULA-2 +/+ counterparts ( Figure 1E ). Similar to TULA-2 complete knockout, but to a lesser degree, TULA-2 +/− murine platelets showed significantly increased Syk phosphorylation, PLCγ2 phosphorylation, and LAT phosphorylation compared with TULA-2 +/+ platelets ( Figure 1C , 1D, and 1G). Collagen-related peptide (CRP) activates platelets via platelet glycoprotein VI (GPVI)/FcRγ receptor, which also signals via Syk, PLCγ2, and LAT. In agreement with previous findings, TULA-2 +/− platelets showed enhanced phosphorylation of Syk and LAT in response to CRP stimulation compared with WT ( Figure III in the online-only Data Supplement). These data indicate that TULA-2 dephosphorylates Syk in both FcγRIIA and GPVI pathways in platelets in a manner dependent on TULA-2 levels.
TULA-2 Regulates Platelet Aggregation on FcγRIIA Activation
We evaluated the role of TULA-2 in FcγRIIA-mediated platelet aggregation. Consistent with previous studies, 21, 22 anti-CD9 antibody induced platelet aggregation in all 3 groups of mice ( Figure 2 ). We observed significant differences in the duration of aggregation lag time between the 3 genotypes. TULA-2 −/− platelets aggregated rapidly within 4 minutes at both concentrations of CD9 treatment (Figure 2A and 2B), whereas TULA-2 +/− platelets took 7 and 5 minutes to aggregate in response to low and moderate concentration of CD9, respectively (Figure 2A and 2B ). In comparison, it took 11 and 8 minutes for TULA-2 +/+ platelets to start aggregation Syk spleen tyrosine kinase TULA-2 T-cell ubiquitin ligand-2 (also known as Sts-1, encoded by UBASH3B gene)
WT wild-type (Figure 2A , 2B, and 2E). As negative controls, thrombininduced platelet aggregation in all 3 groups showed no difference in the duration of lag time ( Figure 2C and 2D).
Decreased TULA-2 Expression Enhances Platelet Reactivity via FcγRIIA
Downstream effects of FcγRIIA signaling include integrin activation, calcium mobilization, granule secretion, and phosphatidylserine exposure. Integrin α IIb β 3 activation enables platelet-fibrinogen binding and clot formation, and it is one of the crucial processes in platelet activation and hemostasis. 23 The surface expression level of FcγRIIA was not changed by TULA-2 knockout ( Figure 2F ). We used flow cytometry to evaluate integrin activation, P-selectin expression, and phosphatidylserine exposure in platelets. Integrin activation was assessed by JON/A antibody, which binds to the activated integrin α IIb β 3 but not the resting conformation. Different doses of IV.3+GAM or CRP were used to stimulate washed platelets. Compared with TULA-2 +/+ , TULA-2 −/− murine platelets showed enhanced integrin α IIb β 3 activation at a dose of 1 µg/ Figure 3A and 3C). Furthermore, integrin α IIb β 3 activation was also amplified in TULA-2 +/− platelets compared with TULA-2 +/+ ones under the same concentration of agonists ( Figure 3C ). In contrast, TULA-2 −/− and TULA-2 +/+ platelets did not show differential reactivity in response to 0.01 or 0.05 U/mL thrombin, which signals through protease-activated receptor 4 in murine platelets ( Figure 3B ). Higher concentration of CRP (2 µg/mL) resulted in full activation of platelet integrin in both genotypes, indicating that the TULA-2 regulates the threshold of platelet integrin activation but not the maximum potential of inside-out signaling. Platelet α-granules contain various important proteins, including growth factors, platelet factor 4, clotting factors, and fibrinogen. 24, 25 During platelet activation, α-granules release their contents, and α-granule membranous markers, such as P-selectin, are relocated to the plasma membrane and can be detected by flow cytometry. When stimulated by antimouse CD9 antibody, TULA-2 −/− and TULA-2 +/− platelets demonstrated significantly higher expression level of P-selectin compared with the WT (Figure 3D ), indicating that the activity of TULA-2 affects platelet α-granule secretion.
In resting platelets, phosphatidylserine normally resides on the cytoplasmic side of the plasma membrane. During platelet activation, sustained calcium influx causes the translocation of phosphatidylserine onto the outer surface of the platelet membrane, providing negatively charged surface for thrombin activation and binding of coagulation factors. 26, 27 Phosphatidylserine exposure is induced by dual stimulation with 1 G-protein-coupled receptor agonist and 1 ITAM agonist. 28 In this study, we used thrombin plus anti-CD9 to promote phosphatidylserine exposure. A greater population of phosphatidylserine-positive platelets were observed in TULA-2 −/− and TULA-2 +/− groups in comparison with the TULA-2 +/+ control ( Figure 4A and 4B ).
TULA-2 Reduction Potentiates HIT-Like Thrombocytopenia and Thrombin Activation In Vivo
We previously used anti-GPIX or anti-CD9 antibodies to induce HIT-like symptoms in vivo. 21, 22 Anti-GPIX or anti-CD9 antibodies activate platelets via FcγRIIA and lead to thrombocytopenia and thrombosis. 22 In this study, we injected 3 µg antimouse GPIX antibodies per 20 g mouse to 3 cohorts of mice and measured the platelet count after indicated time periods. Compared with TULA-2 +/+ mice, both TULA-2 −/− and TULA-2 +/− mice displayed a significantly greater reduction in platelet counts at 1, 4, and 24 hours ( Figure 5A ).
The serum level of the thrombin-antithrombin (TAT) complex correlates well with thrombin activation, the severity of intravascular platelet activation, and coagulation. 29, 30 We measured the TAT concentration in the 3 cohorts of mice after anti-GPIX antibody treatment by ELISA assay. At resting state, TULA-2 −/− or TULA-2 +/− mice did not show a significant difference in TAT levels compared with TULA-2 +/+ mice. One hour and 4 hours after anti-GPIX antibody treatment, TULA-2 −/− mice had significantly greater increase in TAT complex concentration (2.8-and 5.9-fold increase, respectively) than the TULA-2 +/+ mice (1.9-and 2.0-fold increase, respectively; Figure 5B ).
Using a second immune-mediated thrombocytopenia and thrombosis model, we noted that anti-CD9 antibody-treated mice also showed significant differences in thrombocytopenia and TAT levels between TULA-2 −/− and TULA-2 +/+ mice ( Figure IV in the online-only Data Supplement). Together, these data show that TULA-2 plays a crucial role in modulating platelet activation and thrombosis in vivo.
Reduced TULA-2 Shortens Tail Bleeding Time
Tail bleeding time is a widely accepted method to evaluate platelet function, in vivo hemostasis and the risk of bleeding. 31 In this study, a distal 5 mm segment of the tail was amputated, and the duration of active bleeding was recorded in each mouse. In the TULA-2 +/+ group, the mean bleeding time±SE was 217.5±25.7 s, whereas for TULA-2 −/− and TULA-2 +/− , the bleeding time were significantly shortened, at 99.3±19.2 and 150.1±13.7 s ( Figure 5C ; *P<0.05 and **P<0.01, respectively).
Knockout of TULA-2 May Not Affect the Platelet Outside-In Signaling
Platelet integrin α IIb β 3 transmits activating signals into the cells after binding to fibrinogen, fibrin or vWF, via platelet outsidein signaling. FcγRIIA has been demonstrated to function as a cooperative adaptor for the α IIb β 3 in outside-in signaling. 5 The role of TULA-2 in the outside-in pathway in FcγRIIA transgenic murine platelets has not been reported. We studied TULA-2 −/− or TULA-2 +/+ platelets spreading on immobilized fibrinogen without agonists. There were no differences in total number of spread platelets or the area occupied by platelets between the 2 genotypes at 15, 30, or 60 minutes (Figure 6A , 6B, and 6C). We also investigated the role of TULA-2 in the integrin outside-in signaling in the present of thrombin or 2-MeSAMP, a P2Y 12 blocker. Consistent with previous studies, 32,33 low dose of thrombin increased and 2-MeSAMP partially inhibited the spreading ability of platelets in both the groups. However, no significant differences were observed between the TULA-2 −/− and TULA-2 +/+ groups ( Figure V in the online-only Data Supplement). In addition, we probed for the phosphorylation of Syk and PLCγ2 after FcγRIIA-positive platelet spreading on fibrinogen without agonists. TULA-2 knockout did not change the level of Syk or PLCγ2 phosphorylation ( Figure VI in the online-only Data Supplement).
Under normal physiological wound healing process, platelets gradually retract and form dense fibrin-platelet plugs to prevent further blood loss and protect deeper tissue for healing. 34, 35 Therefore, we studied clot retraction, another readout for platelet outside-in signaling. Platelet-rich plasma isolated from TULA-2 −/− or TULA-2 +/+ mice were stimulated with 1 U/mL thrombin, and retraction was measured. At each time point, the sizes of the clot were comparable between TULA-2 −/− and TULA-2 +/+ mice, and no significant difference was detected ( Figure 6D and 6E) . These data suggest that platelet outside-in signaling may not be affected by the absence of TULA-2.
Discussion
Understanding the regulation of the platelet FcγRIIA pathway is important for deciphering the pathogenesis of FcγRIIAmediated thrombotic disorders and developing novel therapeutic methods. In this study, we identified TULA-2 as a negative regulator of the FcγRIIA pathway in murine Figure 5 . T-cell ubiquitin ligand-2 (TULA-2) level regulates Fc receptor for IgG IIA-mediated thrombocytopenia, thrombin generation, and tail bleeding time in vivo. A, A measure of 3 µg anti-GPXI antibody per 20 g mouse body weight was used in 3 groups of 8 mice each via retro-orbital injections. Whole blood was collected at indicated time. Platelet count was plotted against time. TULA-2 +/− and TULA-2 −/− mice both exhibited significantly more severe platelet drop than the wild-type control (n=3, *P<0.05, **P<0.01, 2-way ANOVA). B, Plasma was obtained from the whole blood at different time after anti-GPXI antibody injection. Thrombin-antithrombin (TAT) complex concentration was measured and normalized to standard control by ELISA. Fold changes of TAT normalized to pre-GPXI treatment was plotted against time. TULA-2 −/− mice showed significantly higher TAT concentration compared with TULA-2 +/+ mice at 1 and 4 h (n=3, *P<0.05, Student t test). C, Tail bleeding time of each mouse was recorded as duration from tail amputation to the first cessation of bleeding longer than 1 min (n=8 for TULA-2 −/− and TULA-2 +/+ , n=12 for TULA-2 +/− , *P<0.05, **P<0.01, Student t test). platelets, via the dephosphorylation of Syk. Knockout of TULA-2 resulted in enhanced ITAM-specific platelet integrin activation, α-granule secretion, phosphatidylserine exposure, and platelet aggregation. Anti-GPIX or anti-CD9 antibody treatment mimics the pathogenesis of HIT, in which the Fc portion of the antibodies bound to platelets activates adjacent platelets via FcγRIIA. 21, 22 We observed worsened thrombocytopenia and increased thrombin generation in TULA-2 −/− mice compared with TULA-2 +/+ ones, which indicates TULA-2 is necessary for controlling overactivation of FcγRIIA-mediated platelet activation in HIT. Tail bleeding time correlates well with in vivo platelet function necessary to achieve hemostasis. 36 The observed reduction of tail bleeding time in TULA-2-deficient mice is in accordance with previous findings, 20 and it suggests that TULA-2 not only regulates thrombosis but also functions in the physiological process of cessation of blood loss. Multiple factors contribute to the duration of bleeding time. We believe that the effect of TULA-2 level on tail bleeding time is mainly because of amplified platelet GPVI pathway, phosphatidylserine exposure, and activation of the coagulation cascade. It is possible, however, that the knockout of TULA-2 in other cell types also contributes to the improved hemostasis.
Our findings extend the knowledge of TULA-2 and HIT by showing for the first time that TULA-2 regulates the platelet FcγRIIA pathway. Known targets of TULA-2, a protein tyrosine phosphatase, include Syk and ZAP-70. 20, [37] [38] [39] [40] Our data on hyperphosphorylation of Syk Y519/520 after FcγRIIA activation are consistent with previous studies in the platelet GPVI pathway. 20, 41 In contrast, platelet G-protein-coupled receptor pathways were shown to be unaffected by TULA-2 knockout. 20 All together, TULA-2 is indicated to be an ITAM-specific negative modulator in platelets. Hyperphosphorylation of PLCγ2 and LAT are most likely because of hyperactivation of Syk because PLCγ2 and LAT have not been shown as direct targets of TULA-2. Currently, no TULA-2 inhibitors were tested in animals or humans. Luis and Carpino 42 designed TULA-2 substratetrapping mutants that can inhibit T-cell receptor signaling in T cells. A small-molecule TULA-2 inhibitor would benefit the understanding of the ITAM-Syk signaling and thrombosis in general.
Integrin α IIb β 3 is a major integrin in platelets. Here, we demonstrated that the lack of TULA-2 potentiated integrin inside-out signaling followed by FcγRIIA and GPVI stimulation. Previous studies reported that FcγRIIA-transgenic murine platelets demonstrated better platelet spreading and better clot retraction ability compared with WT mice that lack the FCGR2A gene. 5, 43 Syk inhibitors and ADP-P2Y 12 inhibitors (2-MeSAMP) have also been shown to impede outside-in signaling. 17, 32, 44 Considering integrin α IIb β 3 utilizes FcγRIIA and Syk in outside-in signaling, [45] [46] [47] the finding that TULA-2 knockout did not affect the integrin outside-in signaling in the various conditions tested suggests that multiple mechanisms are at play and requires further investigation. However, our data may not be sufficient to completely rule out a role of TULA-2 in the integrin α IIb β 3 outside-in pathway.
The role of TULA-2 in other diseases or cell types is of great interest. Bacteria can induce platelet activation and immune responses via FcγRIIA and integrins. 6, 7 The question of whether TULA-2 mediates platelet-bacteria interaction necessitates further exploration. TULA-2 might prevent overactivation of platelets and amplification of inflammatory response in the presence of bacteria as seen in sepsis given its role in quenching FcγRIIA overstimulation. Recent studies have discovered the importance of monocyte activation in HIT pathogenesis, in which HIT antibodies stimulate monocyte FcγRIIA-mediated tissue factor production and further facilitates coagulation cascade activation and thrombosis. 48, 49 Further experiments are necessary to determine whether TULA-2 regulates monocyte activation via FcγRIIA.
TULA-2 heterozygous knockout (+/−) mice exhibited significantly enhanced FcγRIIA-and GPVI-induced platelet activation, exacerbated HIT symptoms, and shortened bleeding time compared with the WT. The phenotypic difference between TULA-2 +/− and TULA-2 +/+ mice may be important for advancing our findings to the human population. We reported that platelets from human hyporesponsive donors to FcγRIIA have twice as much TULA-2 protein as those whose platelets are hyper-responsive. 19 The 2-fold variation in TULA-2 protein between the TULA-2 HET and WT mice serves as a potentially ideal model for studying human hyper-and hyporesponders. HIT is a paradigm of the immune-mediated thrombocytopenia and thrombosis diseases, which are characterized by intravascular activation of various cell types and thrombus formation in response to the activation of the immune system. 8 Identification of the determinants of the variable platelet TULA-2 levels in humans could advance our understanding of the susceptibility to immune-mediated thrombocytopenia and thrombosis disorders in general.
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